[go: up one dir, main page]

WO2002011761A3 - Vaccin contre le virus respiratoire syncytial (rs) - Google Patents

Vaccin contre le virus respiratoire syncytial (rs) Download PDF

Info

Publication number
WO2002011761A3
WO2002011761A3 PCT/US2001/041633 US0141633W WO0211761A3 WO 2002011761 A3 WO2002011761 A3 WO 2002011761A3 US 0141633 W US0141633 W US 0141633W WO 0211761 A3 WO0211761 A3 WO 0211761A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
protein
vaccine against
against rsv
rsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/041633
Other languages
English (en)
Other versions
WO2002011761A2 (fr
Inventor
James J Mond
Gregory Prince
Dennis M Klinman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority to AU2001285421A priority Critical patent/AU2001285421A1/en
Publication of WO2002011761A2 publication Critical patent/WO2002011761A2/fr
Publication of WO2002011761A3 publication Critical patent/WO2002011761A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un vaccin comprenant des oligodidésoxynucléotides (ODN) adjuvants, renfermant au moins un dinucléotide CpG et un antigène qui comporte une séquence peptidique porteuse d'au moins un épitope de protéine F de Paramyxoviridae. Selon une variante, l'ODN est mélangé et conjugué à une protéine F de virus RS. Le vaccin peut être administré directement au tissu des muqueuses des voies respiratoires, par inhalation ou voie intranasale.
PCT/US2001/041633 2000-08-10 2001-08-09 Vaccin contre le virus respiratoire syncytial (rs) Ceased WO2002011761A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001285421A AU2001285421A1 (en) 2000-08-10 2001-08-09 Vaccine against rsv

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22401100P 2000-08-10 2000-08-10
US60/224,011 2000-08-10
US22930700P 2000-09-01 2000-09-01
US60/229,307 2000-09-01

Publications (2)

Publication Number Publication Date
WO2002011761A2 WO2002011761A2 (fr) 2002-02-14
WO2002011761A3 true WO2002011761A3 (fr) 2003-01-23

Family

ID=26918345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/041633 Ceased WO2002011761A2 (fr) 2000-08-10 2001-08-09 Vaccin contre le virus respiratoire syncytial (rs)

Country Status (2)

Country Link
AU (1) AU2001285421A1 (fr)
WO (1) WO2002011761A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8466116B2 (en) * 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002555A1 (fr) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Oligonucleotides immunomodulateurs
WO1999061056A2 (fr) * 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methodes et produits permettant d'induire une immunite au niveau des muqueuses
WO2000062802A2 (fr) * 1999-04-20 2000-10-26 Smithkline Beecham Biologicals Sa Vaccin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002555A1 (fr) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Oligonucleotides immunomodulateurs
WO1999061056A2 (fr) * 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methodes et produits permettant d'induire une immunite au niveau des muqueuses
WO2000062802A2 (fr) * 1999-04-20 2000-10-26 Smithkline Beecham Biologicals Sa Vaccin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HANCOCK G E ET AL: "CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV)", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 32, 14 September 2001 (2001-09-14), pages 4874 - 4882, XP004303185, ISSN: 0264-410X *
TEBBEY P W ET AL: "A NOVEL AND EFFECTIVE INTRANASAL IMMUNIZATION STRATEGY FOR RESPIRATORY SYNCYTIAL VIRUS", VIRAL IMMUNOLOGY, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 12, no. 1, 1999, pages 41 - 45, XP001055775, ISSN: 0882-8245 *

Also Published As

Publication number Publication date
AU2001285421A1 (en) 2002-02-18
WO2002011761A2 (fr) 2002-02-14

Similar Documents

Publication Publication Date Title
WO2001068116A3 (fr) Prevention et traitement d'infections respiratoires virales au moyen de sequences polynucleotidiques immunomodulatoires
WO2002028422A3 (fr) Vaccin
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
WO2001060402A3 (fr) Vaccin antigrippal a base de proteosomes
WO2000062800A3 (fr) Vaccins
WO2002080965A3 (fr) Composition vaccinale
DE69426077D1 (de) Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
WO2001092470A3 (fr) Vecteurs d'expression d'adn et procedes d'utilisation
WO2002028428A3 (fr) Composition vaccinale
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
AU2002336148A1 (en) Novel peptides of the respiratory syncytial virus (RSV) G protein and their use in a vaccine
WO2003039595A3 (fr) Modeles ameliores de vaccins administrables par voie muqueuse et modes d'utilisation
EP2066332A4 (fr) Vaccin contre la grippe constitué d'un mélange de mannane et d'antigène de la grippe
WO2002087494A3 (fr) Nouveau vaccin
AU2001263443A1 (en) F-protein epitope-based vaccine for respiratory syncytial virus infection
WO2000035481A3 (fr) Composition immunogene polyvalente contenant une composition de sous-unite de rsv et une preparation d'influenzavirus
DE69828801D1 (de) Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus
Hancock et al. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV)
WO2001078787A3 (fr) Vaccin conjugue anti-sepsie
WO2002058725A3 (fr) Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
WO2002011761A3 (fr) Vaccin contre le virus respiratoire syncytial (rs)
WO2000062802A3 (fr) Vaccin
FI952445A0 (fi) Pneumokokiantigeenien annostelu limakalvojen kautta
WO2001070265A3 (fr) Adjuvants lipopeptidiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP